STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 249,503 shares of the business's stock in a transaction on Monday, March 3rd. The shares were purchased at an average cost of $16.64 per share, for a total transaction of $4,151,729.92. Following the transaction, the insider now owns 11,953,198 shares of the company's stock, valued at $198,901,214.72. This trade represents a 2.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
- On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The stock was acquired at an average price of $15.49 per share, with a total value of $565,880.68.
- On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The shares were acquired at an average cost of $14.96 per share, for a total transaction of $3,883,855.36.
- On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The stock was acquired at an average cost of $21.50 per share, with a total value of $176,751.50.
- On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The shares were bought at an average cost of $21.46 per share, for a total transaction of $453,986.30.
- On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The shares were bought at an average cost of $24.33 per share, with a total value of $559,590.00.
- On Monday, December 16th, Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock. The stock was bought at an average price of $24.24 per share, for a total transaction of $1,296,840.00.
STAAR Surgical Trading Down 5.9 %
Shares of STAAR Surgical stock opened at $16.47 on Tuesday. The company has a 50-day moving average of $21.55 and a two-hundred day moving average of $27.18. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68. The stock has a market cap of $812.38 million, a PE ratio of -40.17 and a beta of 0.62.
Hedge Funds Weigh In On STAAR Surgical
Several hedge funds have recently bought and sold shares of the company. Arcadia Investment Management Corp MI purchased a new stake in STAAR Surgical during the third quarter worth $37,000. Quarry LP acquired a new position in shares of STAAR Surgical during the 3rd quarter worth $50,000. Quest Partners LLC acquired a new position in shares of STAAR Surgical during the 3rd quarter worth $128,000. Van ECK Associates Corp boosted its position in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock worth $129,000 after buying an additional 393 shares in the last quarter. Finally, Larson Financial Group LLC grew its stake in STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier's stock valued at $181,000 after acquiring an additional 2,135 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Jefferies Financial Group downgraded STAAR Surgical from a "buy" rating to a "hold" rating in a report on Wednesday, February 12th. Mizuho cut shares of STAAR Surgical from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. Canaccord Genuity Group dropped their price target on shares of STAAR Surgical from $28.00 to $17.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. BTIG Research downgraded shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 12th. Finally, StockNews.com lowered STAAR Surgical from a "hold" rating to a "sell" rating in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, STAAR Surgical presently has a consensus rating of "Hold" and an average price target of $26.86.
Get Our Latest Stock Analysis on STAAR Surgical
STAAR Surgical Company Profile
(
Get Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
